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Introduction:  In Brazil, about 26,000 cases of colorectal cancer are diagnosed per year. Pa-
tients considered at the early stage of disease (without lymph node) evolve with tumor 
relapse or recurrence in up to a quarter of cases, probably due to understaging. Objective: 
Research on ex vivo sentinel lymph node in patients with colorectal adenocarcinoma.
Materials and methods:  We studied 37 patients who underwent curative surgical resection. 
The marker used to identify lymph nodes was patent blue dye injected into the peritu-
moral submucosa of the open surgical specimen immediately after its removal from the 
abdominal cavity. 
Results:  Ex vivo identification of sentinel lymph node with marker occurred in 13 (35.1%) 
patients. The sensitivity was 40% and 60% false negative. The detailed histological examina-
tion of sentinel lymph nodes with multilevel section and immunohistochemistry showed 
metastasis in one (4.3%) individual, considered ultra-staging.
Conclusion:  The ex vivo identification of sentinel lymph node had questionable benefits, and 
worse results when include patients with rectal cancer. Restaging of one patient was possible 
after multilevel section and immunohistochemistry of the sentinel lymph node, but more 
research is needed to evaluate the role of micrometastases in patients with colorectal cancer.
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r e s u m o
Pesquisa do linfonodo-sentinela ex vivo no câncer colorretal
Introdução: No Brasil, a cada ano são diagnosticados cerca de 26.000 casos de câncer colorre-
tal. Pacientes com estadiamento considerado inicial, sem linfonodo metastático, evoluem 
com recorrência ou recidiva do tumor em até um quarto dos casos, por provável subesta-
diamento. Objetivo: pesquisar sobre linfonodo-sentinela ex vivo em pacientes com adeno-
carcinoma colorretal.
Objetivo: Foram estudados 37 pacientes, submetidos à cirurgia oncológica com ressecção 
caráter curativo. O marcador de linfonodos utilizado foi o corante azul patente, injetado na 
submucosa peritumoral da peça cirúrgica aberta imediatamente depois de sua retirada da 
cavidade abdominal.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Pacientes e métodos: A identificação ex vivo de linfonodo-sentinela com o marcador ocorreu 
em 13 (35,1%) pacientes. A sensibilidade do método foi de 40% e o falso negativo de 60%. 
O exame histológico pormenorizado dos linfonodos-sentinela com multissecção e imu-
noistoquímica diagnosticou metástase em um (4,3%) indivíduo, sendo considerado ultra-
-estadiamento. 
Resultados: A identificação de linfonodo-sentinela ex vivo apresenta benefícios questioná-
veis, e piores resultados quando são incluídos pacientes com câncer de reto. Foi possível 
reestadiamento de um paciente depois da realização de multissecção e imunoistoquímica 
de linfonodos-sentinela, mas mais trabalhos são necessários para estabelecer a importân-
cia das micrometástases em pacientes com câncer colorretal.
Introduction
Colorectal cancer incidence worldwide is 1.2 million cases per 
year, according to the World Health Organization.1
Sentinel lymph node is considered the first receiving lym-
phatic drainage from the tumor and thus more likely to con-
tain metastases.2 
The treatment of colorectal cancer is surgical, and study 
of lymph nodes in critically ill individuals has shown that ad-
juvant chemotherapy increases the disease-free survival of 
patients with lymph node metastasis.3,4 
However, the literature provides a challenge, because 
patients with colorectal cancer treated at the early stage, 
without lymph node histology routine; therefore, with no 
indication for adjuvant therapy, progress with local tumor 
recurrence or distant metastases in up to 25% of cases.5–7 
This fact makes us think about a possible understaging and 
imposes the need to examine lymph nodes more closely by 
identifying the sentinel lymph nodes and, adding to the rou-
tine histology, a detailed study with multilevel sectioning and 
immunohistochemistry. 
The identification of sentinel lymph node can be done in-
traoperatively (in vivo) or in surgical specimen (ex vivo) using 
dyes and/or radiopharmaceuticals with tropism for lymph 
nodes. This study, which is unprecedented in Brazil, has been 
researching on ex vivo sentinel lymph node using dye.
Patients and methods
This is a prospective, descriptive and analytical study of senti-
nel lymph node in patients undergoing colorectal cancer with 
proposed curative surgery.
It involved 37 patients with colorectal cancer, operated 
from November 2008 to April 2012 in two institutions: Hospital 
Alberto Cavalcanti, which belongs to the state public health of 
the Fundação Hospitalar do Estado de Minas Gerais (FHEMIG); 
Hospital da Polícia Militar do Estado de Minas Gerais, which 
serves the military police and their dependents, both located 
in the city of Belo Horizonte, MG, Brazil. 
The study was approved by the Ethics Committee of the 
Hospitals and the Universidade Federal de Minas Gerais.
Inclusion criteria were patients with colon or rectum can-
cer; over 21 years of age, adherence to informed consent. Ex-
clusion criteria were evidence of distant metastasis, urgent 
surgery, or patient’s refusal to participate.
Surgical procedure and identification of sentinel lymph node
The procedure was general anesthesia, antisepsis, laparot-
omy, and oncologic resection of the bowel segment and its 
mesentery containing the tumor. The surgical specimen was 
removed from the abdominal cavity, The searching process 
for sentinel lymph nodes was as follows: a) placing the speci-
men removed in a surgical table; b) immediate opening of the 
intestinal lumen to locate the tumor; c) injection of 1 mL of 
patent blue dye 1% (manufactured by Citopharma Ltda. – Belo 
Horizonte, MG, Brazil), in the peritumoral submucosa, the vol-
ume of dye was divided equally and applied to the four cardi-
nal points around the lesion, using 1 mL syringe and needle 
13 x 4.5 mm (Fig. 1); d) peritumoral massage for 5–10 minutes; 
e) identification by direct visualization of the first blue lymph 
nodes (Fig. 2), which are considered sentinel lymph nodes, 
and then marked with surgical thread. 
All marked sentinel lymph nodes were removed from the 
mesentery and sent separately in numbered vials, along with 
the surgical specimen, to the pathology service. 
Histological examination of all lymph node started with 
routine histology. Lymph nodes were embedded in paraffin 
blocks cut with a microtome, placed on slides, stained with 
hematoxylin-eosin and examined by light microscopy. In 
the absence of metastases by this method, only the sentinel 
lymph nodes were sent for multilevel section and immuno-
histochemistry examination. 
Fig. 1 – Open specimen, with peritumoral points of patent 
blue dye injection.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Fig. 2 – Intestinal mesentery with visual identification of 
sentinel lymph nodes using patent blue dye.
The technique called multilevel section consists of mul-
tiple cuts of lymph nodes included in paraffin block, stag-
gered at intervals of 2-3 mm, which are then stained with 
hematoxylin-eosin and examined in more detail by light 
microscopy. 
For immunohistochemistry, we used AE1/AE3 cytokera-
tins (Biogenex®). The process phases were as follows: cut-
ting the lymph node to each scaled range of 50  microns; 
immunoperoxidase, streptavidin, biotin Supersensitive after 
antigen-induced heat with EDTA buffer, followed by staining 
control. 
For staging, the pathological tumor-node-metastasis 
(TNM) criteria were followed.8 
Tumors were located at the right colon, twelve (32%); 
transverse colon, one (3%); sigmoid colon, two (6%); and rec-
tum, twenty-two (59%). The size ranged from 1–11 cm, with a 
mean of 3.5 cm (SD = 1.9).
Results
Identification of lymph node using dye
In the 37 study patients, 415 lymph nodes were isolated, 
mean 11 (SD = 5.7) per patient. The patent blue sentinel lymph 
node was identified in 13 (35.1%) individuals. We identified 29 
sentinel lymph nodes ex vivo using dye, with a mean of 2.2 
(SD = 1.7) per patient (Table 1).
Dye and histology 
Among the 29 sentinel lymph nodes identified using dye, 
histological examination of routine hematoxylin-eosin diag-
nosed metastases in 2 (6.8%) and the other 27 (93.2%) had no 
signs of metastases. Of the 386 non-sentinel nodes, 31 (8%) 
had metastases, 355 (92%) were free of metastasis (Table 2). 
Considering the validity study, in 13 patients with sentinel 
lymph nodes identified using dye, routine histological exami-
nation identified metastases in five (38.4%). Of this group of 
five patients, one (20%) had metastases exclusively located in 
sentinel lymph nodes, one (20%) had metastases in both sen-
tinel and non-sentinel lymph nodes, and three (60%) had me-
tastases in non-sentinel lymph nodes, the latter figure repre-
sents the false negative. In the other eight patients, despite 
the identification of sentinel lymph nodes, no metastases 
were diagnosed by routine histology with hematoxylin-eosin 
(Table 3). 
Staging of patients
The routine histological examination did not diagnose me-
tastasis in 23 (62.1%) of 37 patients, so they were considered 
N0 stage. In the other fourteen (37.9%), metastases were diag-
nosed and classified in stage N +. Thus, staging (TNM) initial 
sample was: N0 = 23 patients (62.2%) and N + = 14 patients 
(37.8%). In the group of 23 patients without metastases by 
routine histology (stages I or II), additional tests was done 
in the sentinel lymph node, with multilevel section and im-
munohistochemical, and metastasis was diagnosed in only 
one (4.3%), representing the ultra-staging. Therefore, the final 
staging (TNM) was stage N0 = 22 patients (59.5%) and N + = 15 
patients (40.5%).
Discussion
Technique for ex vivo identification of sentinel lymph node
The correct staging of the intestinal tumor is the major factor 
in patient survival, because when histology identifies lymph 
node metastasis, patients are referred for chemotherapy 
with known decreased recurrence and improved survival.3,4 
Techniques to identify sentinel lymph node in intestinal 
tumors has been described for over half a century.9 But, the 
first studies using the ex vivo technique in colorectal cancer 
were published only a little over ten years.10 In Brazil, there is 
still no publication, a fact that motivated our study. 
Authors who defend the ex vivo method describe its main 
advantages as simple execution; low cost; does not increase 
the operative time; obeys the principle of the cancer ‘no 
touch tumor’; and without risk of adverse effects such as 
anaphylaxis.11–13 
In this study, the success rate in identifying sentinel 
lymph nodes in colorectal cancer was 35.1%. The literature 
credits worse results by: flaws in the injection; advanced 
stage of the lesion; mucinous histological type; location in 
the rectum, and prior radiotherapy.14–16 In this study, two 
thirds of the patients were operated on for rectal tumors, 
and also received chemotherapy + radiotherapy preopera-
tive.
Given the unfavorable results of the study, the investiga-
tion of sentinel lymph node in ex vivo using patent blue dye 
is presented as an option to be held in rectal tumors, even 
with questionable benefits, because it is technically unwork-
able in rectal tumors, or in a complementary manner in co-
lon tumors, when there has been failure with another tech-
nique for identifying sentinel intraoperatively (in vivo). 
Bookmarks
In our study subject of study for master’s thesis at the Universi-
dade Federal de Minas Gerais in 2007, we used patent blue dye 
and radiopharmaceutical for sentinel lymph node  identification 
during surgery in patients with colon cancer. The results showed 
the superiority of radioisotope over the dye.17 
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Vital staining has been used by most authors, because the 
radiopharmaceuticals add high costs (600 dollars each exam) 
and logistics complex.
Number of nodes
The number of lymph nodes examined is of great importance 
for staging, and directly influences treatment and prognosis of 
patients operated on for colorectal cancer. Current literature 
states that to obtain reliable pathology, it should be examined 
at least 10–12 lymph nodes. Publications found five-year sur-
vival of approximately 73% when less than 10 lymph nodes 
were examined, 80% when 11–20 lymph nodes, and 87% with 
more than 20 lymph nodes examined.18 The American Joint 
Committee on Cancer (AJCC) recommends that at least 7–14 
lymph nodes should be examined.8 
In 37 cases studied, we found a mean of 11.2 nodes per 
patient, in accordance with the recommended stage it is suf-
ficient to reliably.19,20 
It is worth noting that in surgical specimens who received ra-
diotherapy, the work is much harder for researcher and patholo-
gist in the search for lymph nodes,21 a fact clearly seen in this 
study, as in one of the patients no lymph node could be studied 
since there were no remaining lymphoid in surgical specimen.
Sensitivity and false negative
In the specific case of sentinel lymph node study for colorectal 
tumors, the adverse findings with high rates of false negative 
did not interfere with the results because the therapeutic radi-
cal lymphadenectomy is always maintained, regardless of the 
presence or absence of metastases in regional lymph nodes. 
In this study, the rate of 60% false negative results was 
found. According to the review work, the average overall rate of 
false negative rate is 33%, ranging from zero to 63%.22–24
According to the study of validity of this study, the sen-
sitivity was 40%, while in the literature it ranges from 40 
to 100%.25–27 
Table 1 – Overall outcome of the study.
Patient Size (cm) Localization Blue LNS Total LN Metastases 
in LNS (H-E)
Metastases 
in LNNS 
(H-E)
Stage TNM MS IQ
1 11 right 00 12 00/00 01/12 III NR NR
2 5.5 right 02 19 00/02 00/17 II Positive Positive
3 5.5 rectum 02 06 00/02 00/04 II Negative Negative
4 2 rectum 00 04 00/00 00/04 II NR NR
5 1.5 rectum 00 06 00/00 00/06 II NR NR
6 4 sigmoid 06 15 00/06 00/09 I Negative Negative
7 4 rectum 00 06 00/00 00/06 II NR NR
8 5 right 00 14 00/00 01/14 III NR NR
9 2.5 rectum 03 07 00/03 00/04 II Negative Negative
10 2.5 rectum 00 04 00/00 00/04 II NR NR
11 6 rectum 01 22 00/01 01/21 III NR NR
12 6 right 00 08 00/00 01/08 III NR NR
13 2 rectum 00 08 00/00 04/08 III NR NR
14 4 rectum 00 05 00/00 00/05 II NR NR
15 2 rectum 00 06 00/00 00/06 I NR NR
16 3.5 rectum 06 11 00/06 01/05 III NR NR
17 1.5 rectum 01 01 01/01 00/00 III NR NR
18 4 right 01 17 00/01 00/16 I Negative Negative
19 5.5 sigmoid 00 15 00/00 00/15 II NR NR
20 2.5 rectum 02 14 00/02 05/12 III Negative Negative
21 2.5 rectum 00 15 00/00 00/15 II NR NR
22 4 rectum 01 25 00/01 00/24 II Negative Negative
23 4 right 01 16 00/01 00/15 II Negative Negative
24 6.5 right 00 15 00/00 00/15 II NR NR
25 3.5 rectum 00 12 00/00 00/12 II NR NR
26 6 right 00 17 00/00 00/17 II NR NR
27 2 rectum 02 15 00/02 00/13 II Negative Negative
28 3 right 00 25 00/00 06/25 III NR NR
29 3 right 00 12 00/00 03/12 III NR NR
30 1 rectum 00 12 00/00 00/12 I NR NR
31 4 rectum 00 09 00/00 00/09 II NR NR
32 1.5 rectum 00 07 00/00 00/07 II NR NR
33 5 right 00 14 00/00 01/14 III NR NR
34 2.5 transverse 01 06 01/01 01/05 III NR NR
35 2.5 rectum 00 05 00/00 01/05 III NR NR
36 3.5 right 00 10 00/00 05/10 III NR NR
37 1 rectum 00 00 00/00 00/00 II NR NR
Total – – 29 415 02/29 31/386 – – –
LN, lymph node; SLN, sentinel lymph node; LNNS, non-sentinel lymph node; HE, hematoxylin-eosin (routine histology); MS, multilevel lymph 
nodes; IQ, immunohistochemistry of lymph nodes; NR, not performed; Blue, dye uptake.
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It is known that the more advanced the tumor, the higher 
will be the rate of false negative and less sensitivity. There-
fore, another possible explanation for these results is that the 
vast majority of patients in this study was treated with prob-
able late diagnoses, whereas 37.8% of patients were already in 
stage III (lymph nodes with metastases) after routine histol-
ogy with hematoxylin-eosin. 
Staging and micrometastases
Instead of a large number of lymph nodes examined un-
der the microscope with few cuts, a detailed examination 
of the sentinel lymph nodes most likely to contain metas-
tases could be performed. The commitment of the patholo-
gist, who carried out multilevel section and/or immunohis-
tochemical tests, increases the sensitivity of the method, 
promotes more adequate patient staging, and is  more cost-
effective.28,29 
Less than 0.5% of the target tissue is removed for routine 
histology, hence the need for rethinking the care and patho-
logical test techniques in colorectal malignancies.30,31 
We believe that all professionals involved in the treat-
ment of malignancies, especially pathologists, need to excel 
in their primary care, devoting more time to their analysis, 
so that patients are allocated in the correct staging. For it is 
known that more compliance with literature recommenda-
tions enables to obtain excellent results without increasing 
costs, just increasing dedication.
In this study, one (4.3%) patient had micrometastases ex-
clusively in sentinel lymph node, after performing addition-
al histological examination, using multilevel section and im-
munohistochemistry. According to authors, it may be a case 
where an individual would benefit from the investigation of 
sentinel lymph node because the disease is diagnosed when 
the chances of providing a cure with adjuvant chemotherapy 
would be greater by attacking the tumor at its initial phase.32 
In an attempt to avoid understaging, special histopatho-
logical techniques with multilevel and immunohistochem-
istry of sentinel lymph nodes may be used. Studies show 
ultra-staging with a wide range of 4%–50%.23,26,33 
Therefore, we need more reliable work and with large 
samples to assess the actual role of micrometastases both 
in evolution and in survival, in addition to know if patients 
operated for colorectal cancer should or not receive adju-
vant therapy in these specials situations.34,35
Conclusions
The ex vivo identification of sentinel lymph node using patent 
blue dye in patients with colorectal cancer had questionable 
benefits. Worse results are obtained when the work includes 
patients operated for rectal cancer, most notably in those who 
undergo radiotherapy. 
Ultra-staging was possible by multilevel section and im-
munohistochemistry of the sentinel lymph nodes. More re-
search is needed to evaluate the role of micrometastases and 
the practical applicability of the method.
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